Here are some of the major companies whose stocks moved on the week’s news.

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...

As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...

Novo Nordisk is also pairing the long-acting insulin with its once-weekly GLP-1 agonist semaglutide in the COMBINE trials programme, which is due to complete in 2024, is also working on a glucose ...

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

$ 78.9079 0.2179 0.28% ...

Riad Sattouf’s saga of his parents’ failed bicultural marriage, with its harsh depiction of life in rural Syria, has become a literary sensation. By Richard Fausset A popular TV host ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Both Democrats will remain in Washington, D.C., where nomination votes are on the docket for ...